STELLA PHARMA CORPORATION [4888.T]
TOKYO, May 18 (Pulse News Wire) – Stella Pharma Corporation (4888.T) announced today the commencement of a domestic Phase III clinical trial targeting recurrent glioblastoma patients who have undergone radiation therapy and temozolomide treatment. The trial, conducted in collaboration with Osaka Medical College and Sumitomo Heavy Industries, aims to evaluate the efficacy and safety of Boron Neutron Capture Therapy (BNCT).
The trial involves 48 cases and will utilize the company’s investigational drug “Borofaran (10B)” (SPM-011) and Sumitomo's BNCT irradiation device (BNCT30) along with its treatment planning program (DE-01). It is scheduled to conclude by June 30, 2030. Funding for this development is part of the proceeds from the issuance of shares and subscription rights disclosed on March 31, 2026, specifically allocated towards rare cancer-related clinical trial expenses amounting to ¥148.9 million.
In addition to providing the necessary investigational drugs free of charge, Stella Pharma will also support data analysis and application preparation for regulatory approval. The company expects minimal impact on its fiscal year ending March 2027 performance due to this initiative. Further updates will be communicated promptly as needed.
🟢 Confidence: High AI-translated content.